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Abstract
Background: Chronic pain is often associated with microglia activation in the spinal cord. We recently showed
that microglial levels of the kinase G protein–coupled receptor kinase (GRK)2 are reduced in models of chronic pain.
We also found that mice with a cell-specific reduction of around 50% in GRK2 level in microglia/macrophages
(LysM-GRK2+/− mice) develop prolonged inflammatory hyperalgesia concomitantly with ongoing spinal microglia/
macrophage activation. The microRNA miR-124 is thought to keep microglia/macrophages in brain and spinal cord
in a quiescent state. In the present study, we investigated the contribution of miR-124 to regulation of hyperalgesia
and microglia/macrophage activation in GRK2-deficient mice. In addition, we investigated the effect of miR-124
on chronic inflammatory and neuropathic pain in wild-type (WT) mice.
Methods: Hyperalgesia was induced by intraplantar IL-1β in WT and LysM-GRK2+/− mice. We determined spinal
cord microglia/macrophage miR-124 expression and levels of pro-inflammatory M1 and anti-inflammatory M2
activation markers. The effect of intrathecal miR-124 treatment on IL-1β-induced hyperalgesia and spinal M1/M2
phenotype, and on carrageenan-induced and spared nerve injury-induced chronic hyperalgesia in WT mice
was analyzed.
Results: Transition from acute to persistent hyperalgesia in LysM-GRK2+/− mice is associated with reduced spinal
cord microglia miR-124 levels. In our LysM-GRK2+/− mice, there was a switch towards a pro-inflammatory M1
phenotype together with increased pro-inflammatory cytokine production. Intrathecal administration of miR-124
completely prevented the transition to persistent pain in response to IL-1β in LysM-GRK2+/− mice. The miR-124
treatment also normalized expression of spinal M1/M2 markers of LysM-GRK2+/− mice. Moreover, intrathecal
miR-124 treatment reversed the persistent hyperalgesia induced by carrageenan in WT mice and prevented
development of mechanical allodynia in the spared nerve injury model of chronic neuropathic pain in WT mice.
Conclusions: We present the first evidence that intrathecal miR-124 treatment can be used to prevent and treat
persistent inflammatory and neuropathic pain. In addition, we show for the first time that persistent hyperalgesia
in GRK2-deficient mice is associated with an increased ratio of M1/M2 type markers in spinal cord microglia/
macrophages, which is restored by miR-124 treatment. We propose that intrathecal miR-124 treatment might be
a powerful novel treatment for pathological chronic pain with persistent microglia activation.
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Background
Micro (mi) RNAs regulate expression of multiple genes
by promoting degradation of mRNA or by preventing
translation of target genes. It has recently been reported
that high levels of the miRNA miR-124 are present in
resident microglia in brain and spinal cord. Ponomarev
et al. showed that microglia activated in vitro and
in vivo have low levels of miR-124. In addition, periph-
eral macrophages, which have an activated phenotype,
express low levels of miR-124 compared with isolated
naive microglia from brain and spinal cord. Based on
such findings, it has been suggested that high levels of
miR-124 are required to keep microglia in a quiescent
state [1].
Microglia/macrophages in the spinal cord play a key
role in the development of chronic pain in rodent mod-
els of neuropathic pain, diabetic neuropathy, and chronic
inflammatory pain [2-7]. However, it is not known
whether microglial miR-124 contributes to chronic pain.
Recently, we reported that chronic inflammatory hy-
peralgesia and neuropathic pain are associated with
decreased levels of the serine–threonine kinase G-protein
receptor kinase (GRK)2 in spinal microglia/macrophages
[8,9]. GRK2 regulates cellular signaling by promoting
desensitization of agonist-occupied G protein-coupled
receptors and by direct interaction with multiple down-
stream signaling pathways [10-14]. Our recent functional
studies indicated a key role for GRK2 in regulating the
transition from acute to persistent hyperalgesia. In mice
with a 50% reduction of GRK2 in microglia/macrophages
(LysM-GRK2+/− mice), thermal and mechanical hyper-
algesia induced by intraplantar injection of inflammatory
mediators were markedly prolonged [8-10,15]. For ex-
ample, thermal hyperalgesia induced by a single intra-
plantar injection of the pro-inflammatory cytokine IL-1β
resolved within 24 hours in wild-type (WT) mice, but
lasted for at least 8 days in LysM-GRK2+/− mice. Simi-
larly, low-dose carrageenan-induced hyperalgesia was
prolonged from 3 to 4 days in WT mice to 20 days in
LysM-GRK2+/− mice. This prolongation of hyperalgesia
in LysM-GRK2+/− mice was reversible by intrathecal
administration of the microglial/macrophage inhibitor
minocycline, indicating a decisive role for spinal cord
microglia/macrophage activity in regulating the transi-
tion to persistent hyperalgesia in these models [8,9].
It is now well known that macrophage activation can
induce development of two functional subtypes known as
pro-inflammatory (M1-type) and anti-inflammatory (M2-
type) macrophages. These two activated types of macro-
phages can be discriminated by the expression of specific
markers on their cell surface, and are characterized by
expression of pro-inflammatory factors such as interleukin
1β, and inducible nitrous oxide synthase (iNOS) (in M1
macrophages) or anti-inflammatory cytokines including
transforming growth factor (TGF)-β (in M2 macrophages).
In addition, there is evidence that microglial activation can
also lead to development of either the M1 or M2 pheno-
type [16,17]. However, it is not known whether or how
these distinct macrophages/microglia phenotypes contrib-
ute to regulation of pain responses.
In this study we investigated whether low levels of
microglial/macrophage GRK2 promote the transition to
chronic hyperalgesia via a miR-124-mediated pathway in
spinal microglia/macrophages, and whether low GRK2 is
associated with the expression of the M1 and M2 pheno-
type in spinal-cord microglia. We also determined
whether miR-124 can be used to treat persistent hyper-
algesia in models of chronic inflammatory and neuro-
pathic pain in WT mice.
Methods
Experiments were performed in accordance with inter-
national guidelines and approved by the experimental
animal committee of UMC Utrecht.
Animals
We used female mice (aged 12 to 14 weeks) with cell-
specific reduction of GRK2 in microglia/macrophages
(LysM-GRK2+/−), and control LysM-GRK2+/+ mice [8,9]
(WT) littermates bred and maintained in the animal
facility of the University of Utrecht, The Netherlands).
LysM-Cre mice and GRK2-fLox mice were obtained
from Jackson Laboratories.
Mice received an intraplantar injection in the hind
paw of 5 μl recombinant murine IL-1β (200 ng/ml;
Peprotech, Rocky Hill, NJ, USA) or 20 μl λ-carrageenan
(2% w/v; Sigma-Aldrich, St. Louis, MO, USA) diluted in
saline. Heat-withdrawal latency times were determined
using the Hargreaves test (IITC Life Science, Woodland
Hills, CA) as described previously [18]. Intraplantar
injection of saline did not induce detectable hyperalgesia
in any of the genotypes.
Spared nerve injury (SNI) was performed in male C57/
bl6 mice as described previously [19]. Briefly, under 2%
isoflurane anesthesia, the sciatic nerve and its three ter-
minal branches were exposed carefully with minimal
damage. Leaving the sural nerve intact, the common
peroneal and the tibial nerves were tightly ligated with
6–0 silk surgical sutures and cut 2 to 4 mm distal to the
ligation. Sham controls underwent anesthesia, incision,
and exposure of the nerve only.
Mechanical allodynia was measured using von Frey
hairs as described previously [9]. The 50% paw-
withdrawal threshold was calculated using the up-and-
down method [20]. In brief, animals were placed on a
wire-grid base, through which the von Frey hairs (Stoelt-
ing, Wood Dale, IL, USA) were applied (bending force
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range from 0.02 to 1.4 g, starting with 0.16 g). The hair
force was increased or decreased depending on the re-
sponse. Clear paw withdrawal, shaking, or licking were
considered as nociceptive-like responses. Ambulation
was considered an ambiguous response, and in such
cases, the stimulus was repeated.
Spontaneous locomotor activity (LMA) was deter-
mined 3 days after SNI in a clean, novel cage similar to
the home cage, but devoid of bedding or litter. The cage
was divided into four virtual quadrants, and LMA was
measured by counting the number of line crossings over
a five-min period.
All behavioral experiments were performed by an experi-
menter blinded to treatment and in a randomized fasion.
The miRNA-124 (2 μg in 50 μl PBS, PM10691Applied
Biosystems, Carlsbad, CA, USA) or control miRNA
(2 μg in 50 μl PBS ,AM17110; Applied Biosystems) was
mixed with transfection reagent (Lipofectamine 2000;
Invitrogen, Paisley, UK) , diluted to the appropriate con-
centration (3 μl in 50 μl PBS) and applied intrathecally
(5 μl/mouse) while the animals were under light isoflur-
ane anesthesia.
Spinal microglia and peripheral macrophage isolation
At 24 hours after intraplantar IL-1β injection, lumbar
enlargements (L2-L5) or thoracic (T6-T10) spinal cord
of four mice were pooled and the microglia were isolated
by Percoll density gradient centrifugation as described
previously [9].
Peripheral macrophages were isolated from peritoneal
lavages using CD11b magnetic beads, in accordance with
the manufacturer’s instructions (BD IMag, San Diego,
CA, USA).
MicroRNA-124 and mRNA expression analysis
Total RNA was isolated using a commercial kit (RNeasy
Mini Kit; Qiagen, Hilden, Germany). Specific reverse
transcriptase and Taqman miRNA assays (Applied Bio-
systems) were carried out in accordance with the manu-
facturer’s instructions. The miR-124 expression (mmu-
miR-124a, 001182) was normalized for snoRNA55
(001228) expression.
Real-time reverse transcriptase PCR
cDNA was processed from total RNA using reverse tran-
scriptase (SuperScript; Invitrogen), and real-time PCR
was performed (iQ5 Real-Time PCR Detection System;
Bio-Rad, Alphen a/d Rijn, The Netherlands) using the
primers shown in Table 1. Data were normalized for
GAPDH and actin expression.
Immunohistochemistry
Mice were perfused intracardially with PBS 15 hours
after intraplantar IL-1β injection, followed by 4%
paraformaldehyde in PBS. Spinal cords were post-fixed
in 4% paraformaldehyde for 6 hours at 4 °C, and cryo-
protected in sucrose. Cryosections (10 μm) of thoracic
segments T6 to T10 and lumbar segments L2 to L5 were
incubated with 1:100 goat anti-mouse CD206 (R&D Sys-
tems, Minneapolis, MN, USA), 1:200 goat anti-mouse
aginase I (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or 1:500 rat anti-mouse CD16/32 (BD Biosciences)
followed by alexa flour 488-conjugated secondary anti-
bodies. Sections were viewed under a fluorescence
microscope (Axio Observer; Zeiss, Jena, Germany). M1
and M2 expression was quantified in approximately 10
to 15 dorsal horns of spinal cords per group (four mice
per group). The level of expression in the lumbar or
thoracic part from control WT mice was set at 100%.
Statistical analysis
All data are presented as mean±SEM. Measurements
were compared using Student’s t-test or two-way ANOVA
with Bonferroni post-hoc tests using Prism 4 software.
Results
MicroRNA-124 expression in spinal cord microglia and
in peripheral macrophages
First, we examined whether the transition from acute
IL-1β-induced hyperalgesia to persistent hyperalgesia in
LysM-GRK2+/− mice is associated with changes in the
level of miR-124 in spinal cord microglia. We isolated
lumbar spinal cord microglia at baseline and 24 hours
after intraplantar IL-1β injection from WT and LysM-
GRK2+/− mice. At this time point, intraplantar IL-
1β-induced hyperalgesia had resolved completely in the
WT mice, whereas the LysM-GRK2+/− mice were still
Table 1 Primers used for real-time reverse transcriptase
PCR.













Abbreviations: C/EBP CCAAT-enhancer-binding protein, GAPDH glyceraldehyde
3-phosphate dehydrogenase, IL interleukin, iNOS inducible nitrous oxide
synthase, TGF transforming growth factor.
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hyperalgesic (Figure 1A). These data confirm our earlier
results [9].
At 24 hours after intraplantar injection of IL-1β,
the level of miR-124 in microglia isolated from the
lumbar spinal cord of LysM-GRK2+/− mice was signifi-
cantly lower than that of spinal microglia from WT mice
(Figure 1B). At baseline (without stimulus), no difference
was seen between WT and LysM-GRK2+/− mice in miR-
124 expression in microglia from spinal cord or in
macrophages from the peritoneal cavity (Figure 1B). In
line with data in the literature, the basal expression of
miR-124 was lower in peripheral macrophages than in
spinal cord microglia [1]. There was no significant differ-
ence in miR-124 mRNA between microglia isolated from
thoracic spinal (T6 to T10) cord of WT and LysM-
GRK2+/− mice after intraplantar IL-1β (data not shown).
Therefore, thoracic spinal cord was used as a control in
subsequent experiments.
It is thought that miR-124 regulates microglia/
macrophage activity by downregulating the expression
of CCAAT-enhancer-binding protein (C/EBP)-α, a tran-
scription factor regulating myeloid cell differentiation
[1,21,22]. Consistent with this notion, we found a signifi-
cant increase in C/EBP-α mRNA in microglia isolated
from the lumbar spinal cord of LysM-GRK2+/− mice
compared with microglia from control WT mice after
intraplantar IL-1β (Figure 1C). C/EBP-α expression was
similar in microglia isolated from control thoracic spinal
cord of LysM-GRK2+/− and control WT mice injected
intraplantarly with IL-1β (Figure 1C).
Spinal cord M1/M2 markers in interleukin-1β-induced
persistent hyperalgesia
We next addressed the question of whether low GRK2
and decreased expression of miR-124 in spinal cord
microglia are related to differences in the expression of
microglia/macrophage activation markers in the spinal
cord. We examined the expression of the markers of the
classically activated (M1) microglia/macrophages CD16/
32 and the alternatively activated (M2) cells arginase-I
Figure 1 MicroRNA-124 and CCAAT-enhancer-binding protein (C/EBP)-α expression after intraplantar interleukin (IL)-1β in wild-type
(WT) and LysM-G protein–coupled receptor kinase (GRK)2+/− mice. Control WT and LysM-GRK2+/− mice received an intraplantar injection of
1 ng IL-1β. (A) Percentage decrease in heat withdrawal latency after the injection in control WT and LysM-GRK2+/− mice (n = 12). At baseline
(n = 9) and 24 hours (n = 6) after IL-1β injection, lumbar (L2 to L5) spinal cord microglia were isolated to determine (B) miR-124 expression
(normalized for small nucleolar (sno)RNA55) and (C) the lumbar and thoracic mRNA expression of C/EBP-α normalized for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and actin) in control WT (n = 6) and LysM-GRK2+/− (n = 6) mice. n =One sample contains isolated microglia
from four mice. Data are expressed as means ± SEM. *P< 0.05, **P< 0.01, ***P< 0.001.
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and CD206 by immunohistochemistry. After intraplantar
injection of IL-1β, expression of the M1 marker CD16/
32 in lumbar spinal cord was higher in LysM-GRK2+/−
mice than in WT mice. There were no differences in M1
marker expression between thoracic spinal cord of WT
and LysM-GRK2+/− (Figure 2A-C). Conversely, the level
of expression of the M2 markers CD206 and arginase-I
after intraplantar IL-1β injection was lower in lumbar
spinal cord of LysM-GRK2+/− mice compared with that
of WT mice. Thoracic spinal cord of both genotypes
did not differ in M2 marker expression (Figure 2A-C).
In control thoracic spinal cord, no genotype-related
differences were seen in the expression of M1 and M2
markers (Figure 2B,C).
As a functional correlate of the M1 and M2 phenotype,
we quantified mRNA encoding the pro-inflammatory
(M1) cytokine IL-1β, the M1-related enzyme iNOS, and
the anti-inflammatory (M2) cytokine TGF-β [23-26]. We
injected LysM-GRK2+/− or WT mice with intraplantar IL-
1β, and isolated microglia from lumbar spinal cord
24 hours later. Compared with control WT mice, freshly
isolated microglia from LysM-GRK2+/− mice contained
significantly more mRNA for pro-inflammatory IL-1β and
iNOS, and less mRNA for anti-inflammatory TGF-β,
Figure 2 M1 and M2 phenotype in spinal cord after intraplantar IL-1β. Wild-type (WT) and LysM-G protein–coupled receptor kinase
(GRK)2+/− mice received an intraplantar injection of 1 ng IL-1β. At 15 hours after injection, spinal cord was collected, and frozen sections of
(A) lumbar spinal cord (L2 to L5) and as control (B) thoracic spinal cord (T6 to T10) were stained for M1 (CD16/32) and M2 (CD206 and arginase-I)
phenotypic markers. A representative example of M1 and M2 staining in the dorsal horn of one of the four mice per group is displayed. Scale bar
indicates 20 μm. (C) Quantification of microglia/macrophages expressing M1 and M2 phenotypic markers in spinal cord from WT and LysM-GRK2
+/− mice. Expression was quantified in approximately 10 to 15 dorsal horns of spinal cords per group (4 mice per group). The level of expression
in the lumbar or thoracic area from control WT mice was set at 100%. Data are expressed as means ± SEM. **P< 0.01, ***P< 0.001.
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(Figure 3). As a control, we isolated microglia from the
thoracic spinal cord of the same animals, and did not ob-
serve any difference in cytokine expression between geno-
types in these cells (Figure 3).
MicroRNA-124 treatment prevents transition to persistent
hyperalgesia in LysM-GRK2+/− mice
To examine the contribution of miR-124 to the course
of hyperalgesia, we treated WT and LysM-GRK2+/− mice
with an intrathecal injection of miR-124, and monitored
its effect on intraplantar IL-1β-induced hyperalgesia.
Intrathecal administration of 50 ng and 100 ng miR-124
completely prevented the transition from acute to per-
sistent IL-1β-induced hyperalgesia in LysM-GRK2+/−
mice (Figure 4A). whereas intrathecal administration
of 100 ng negative control miRNA or the lowest dose of
miR-124 tested (20 ng) did not have any effect on the
course of hyperalgesia in LysM-GRK2+/− mice (Figure 4A).
In WT mice, intrathecal administration of 20 to 100 ng
miR-124 did not have any effect on IL-1β-induced hyper-
algesia (Figure 4B). In addition, baseline thermal sensitiv-
ity was not affected by miRNA administration either
(decrease in heat withdrawal latency; WT plus control
miRNA 2.6± 1.9%; WT plus miR-124 1.8 ± 3.7%; LysM-
GRK2+/− plus control miRNA 2.0± 3.25%; LysM-GRK2+/−
plus miR-124 0.7 ± 3.2%; n= 4).
Role of miR-124 in regulating spinal cord M1/M2 phenotype
After intraplantar IL-1β injection, expression of M1
marker was increased and the expression of M2 marker
was significantly decreased in LysM-GRK2+/− mice com-
pared with WT mice (Figure 2). We hypothesized that
miR-124 treatment would normalize the expression of
the M1 and M2 markers in LysM-GRK2+/− mice. Indeed,
the data clearly showed that miR-124 treatment regu-
lates the M1/M2 balance; the intrathecal miR-124
reversed the difference in the expression of M1 and M2
phenotypic markers between WT and LysM-GRK2+/−
mice in response to intraplantar IL-1β injection (Figure 5).
Effect of microRNA-124 on carrageenan-induced
inflammatory hyperalgesia in wild-type mice
The next question we addressed is whether intrathecal
miR-124 treatment can also reverse the persistent hyper-
algesia that develops in WT mice after intraplantar
injection of carrageenan [8,9,27,28]. WT mice were
still hyperalgesic 6 days after an intraplantar injection
of high-dose λ-carrageenan. Intrathecal treatment with
miR-124 at day 6 rapidly attenuated this persistent
carrageenan-induced thermal hyperalgesia (Figure 6).
Effect of microRNA-124 in a model of neuropathic pain
We used the SNI model of chronic neuropathic pain in
WT mice to investigate the effect of intrathecal miR-124
treatment on mechanical allodynia as assessed by von
Frey filaments. The miR-124 or control miRNA was
injected intrathecally once every day, starting 1 day after
SNI surgery. Mice treated with control miRNA devel-
oped unilateral mechanical allodynia (Figure 7A). The
miR-124 treatment completely prevented the mechanical
allodynia that develops in the ipsilateral paw in response
to SNI (Figure 7A), but did not affect mechanical sensi-
tivity in the contralateral paw (Figure 7B). The miR-124
treatment did not affect spontaneous locomotor
activity of SNI mice as determined in an open field
3 days after SNI (Figure 7C).
Discussion
In this paper, we present a previously unreported role
of miR-124 in the regulation of chronic inflammatory
and neuropathic pain. We found that intraplantar IL-1β
administration to LysM-GRK2+/− mice, which induces
Figure 3 Gene expression of M1-associated and M2-associated genes in spinal microglia after intraplantar injection of interleukin
(IL)-1β. Wild-type (WT) and LysM-G protein–coupled receptor kinase (GRK)2+/− mice received an intraplantar injection of 1 ng IL-1β into the hind
paws. At 24 hours after injection lumbar (L2 to L5) spinal cord and (as a control) thoracic (T6 to T10) spinal cord was collected from WT and
LysM-GRK2+/− mice, and microglia were isolated for analysis of mRNA expression by quantitative RT-PCR of (A) IL-1β, (B) inducible nitrous oxide
synthase (iNOS) and (C) transforming growth factor (TGF)-β (n = 6 quantiatitve PCR samples per group; one sample contains isolated microglia
from 4 mice). Data are expressed as means ± SEM. *P< 0.05, **P< 0.01.
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persistent hyperalgesia, decreased the level of miR-124 in
spinal cord microglia, increased expression of M1 type
phenotypic markers and pro-inflammatory cytokines,
and decreased expression of anti-inflammatory cytokines
and M2 markers.We also showed that intrathecal admin-
istration of miR-124 normalized the M1:M2 ratio and
prevented transition to persistent IL-1β-induced hyper-
algesia in GRK2-deficient mice. Moreover, this is the first
study, to our knowledge, to show that intrathecal miR-
124 treatment reverses persistent carrageenan-induced
hyperalgesia in WT mice. Finally, we found that miR-124
treatment completely inhibits mechanical allodynia in
the SNI model of chronic neuropathic pain. Collectively,
our findings indicate for that miR-124 could represent a
novel treatment for chronic pain.
We showed previously that chronic carrageenan-
induced paw inflammation in WT mice is associated
with a decrease in GRK2 in spinal cord microglia [9].
In addition, in the spinal nerve transection model of
Figure 4 Effect of microRNA (miR)-124 treatment on interleukin
(IL)-1β-induced hyperalgesia. (A) LysM-G protein–coupled receptor
kinase (GRK)2+/− and (B) wild-type (WT) mice received an intrathecal
injection of 20, 50 or 100 ng miR-124 per mouse or 100 ng negative
control miRNA 1 day before intraplantar injection of 1 ng IL-1β and the
percentage change in heat-withdrawal latency was determined (n= 4
to 10 per group). Data are expressed as means± SEM. **P< 0.01,
***P< 0.001 for 50 ng miR-124 versus control miRNA; #P< 0.05,
###P< 0.001 for 100 ng miR-124 versus control miRNA.
Figure 5 MicroRNA-124 treatment influences the M1/M2
balance and abolishes the genotype differences after
interleukin (IL)-1β injection. Mice received an intrathecal injection
of 100 ng miR-124 the day before intraplantar injection of 1 ng IL-1β.
At 15 hours after IL-1β injection, the spinal cord was collected, and
frozen sections of lumbar spinal cord (L2 to L5) were stained for M1
and M2 phenotypic markers. M1 and M2 marker expressions were
compared in wild-type (WT) versus LysM-G protein–coupled receptor
kinase (GRK)2+/− mice, and expression was quantified in 18 dorsal
and 18 lumbar spinal-cord sections per group from 4 mice per
group. The level of expression in IL-1β-treated WT mice was set at
100%. Data are expressed as means± SEM.
Figure 6 Effect of microRNA(miR)-124 treatment on
carrageenan-induced persistent hyperalgesia in wild-type (WT)
mice. Wild-type (WT) mice received an intraplantar injection of 20 μl
2% λ-carrageenan. At day 6, mice were still hyperalgesic. At this time
point, mice received an intrathecal injection of 100 ng miR-124 or
control miRNA, and the percentage change in heat withdrawal
latency was determined (miR-124 n= 8; control miRNA n= 4). Data
are expressed as means ± SEM. ***P< 0.001.
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chronic neuropathic pain in rats, spinal-cord microglial
GRK2 levels are also reduced by approximately 50% [8].
In the current study, we found that intraplantar IL-1β
injection in mice with low microglial/macrophage GRK2
levels induced a reduction in miR-124 expression, lead-
ing to a change in the M1/M2 balance towards a more
pro-inflammatory phenotype and persistent hyperalgesia.
Collectively, our current and previous findings indicate
that the mechanisms involved in transition from acute
to persistent hyperalgesia in the heterozygous GRK2
knockout model may well be applicable to the chronic
pain that develops in more classic models of chronic
pain. Indeed, our present findings show that miR-124
treatment also abrogates the existing persistent hyper-
algesia induced by carrageenan in WT mice. The clinical
relevance is further supported by the current data
showing that miR-124 treatment inhibited the develop-
ment of hyperalgesia in the SNI model of neuropathic
pain supports.
It has been shown recently that intracranial injection
of a miR-124 antisense oligonucleotide inhibitor induced
activation of cerebral microglia [1]. In addition, in vitro
bone marrow-derived macrophages transfected with
miR-124 produced reduced levels of iNOS and increased
levels of TGF-β in conjunction with decreased C/EBP-α
expression. The current study is the first, to our know-
ledge, to show that miR-124 treatment prevents transi-
tion to persistent hyperalgesia in mice with low GRK2
levels in microglia/macrophages. We also found that
treatment with miR-124 reversed the increased M1:M2
ratio that occurred in response to intraplantar IL-1β
in the spinal cord of LysM-GRK2+/− compared with
WT mice. At the functional level, we showed that the
decrease in miR-124 in LysM-GRK2+/− spinal cord micro-
glia in response to intraplantar IL-1β was associated
with increased expression of the pro-inflammatory cyto-
kine IL-1β and the pro-inflammatory enzyme iNOS,
and with decreased expression of the anti-inflammatory
cytokine TGF-β in spinal-cord microglia. At the same
time, C/EBP-α, a ‘master’ transcription factor regulated by
miR-124, was increased in spinal cord microglia from
LysM-GRK2+/− mice after intraplantar injection of IL-1β.
Collectively, our findings support the notion that the
decreased miR-124 expression seen in conditions of low
GRK2 promotes spinal cord microglial/macrophage acti-
vation, leading to an increased M1:M2 ratio and pro-
longed inflammatory hyperalgesia.
The current in vivo data are in line with the results
from in vitro studies reported by Ponomarev et al,
who found that in vitro miR-124 treatment reduces
Figure 7 Effect of miR-124 treatment on SNI-induced mechanical allodynia in WT mice. Spared nerve injury was performed on WT mice
and mice were treated daily with 100 ng miR-124 or control miRNA intrathecally (n = 7 per group). Mechanical allodynia was monitored in (A)
ipsi- and (B) contralateral paw and is depicted as force needed for 50% withdrawal determined in accordance with the up and down method.
Arrows indicate miRNA injection. (C) Spontaneous locomotor activity in an open field was monitored at day three after SNI to control for a
potential effect of miR-124 treatment on motor function. Data are expressed as mean± SEM. *** P< 0.01.
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expression of iNOS and increases TGF-β, arginase I and
Fizz expression by activated bone marrow-derived macro-
phages [1]. Therefore, we propose that miR-124 treatment
reverses hyperalgesia by restoring the ratio of M1:M2
microglia/macrophages.
To our knowledge, this is the first study to describe a
beneficial effect of miR-124 treatment on inflammatory
pain and a decrease in spinal cord microglial miR-124 in
a model of persistent hyperalgesia. A few recent studies
investigated miR-124 expression in other pain models.
Bai et al. showed that miR-124 levels were significantly
reduced in the trigeminal ganglion in a model of
carrageenan-induced muscle pain, indicating that inflam-
matory activity regulates miR-124 in multiple pain models
[29]. Brandenburger et al. reported that total spinal cord
miR-124 was not changed in the chronic constriction
injury model of neuropathic pain [30]; however, because
miR-124 is expressed at a high level in neurons, a poten-
tial change in microglial miR-124 may well have been
masked in that study. In the present study, by contrast,
miR-124 levels were quantified in isolated spinal microglia.
Because we injected miR-124 intrathecally, we cannot
completely exclude that miR-124 also directly affects
other cells in the spinal cord, including sensory neurons.
Notably, however, in control WT mice we did not
observe any effect of miR-124 treatment on the magni-
tude or duration of IL-1β-induced hyperalgesia. More-
over, intrathecal administration of miR-124 did not
affect thermal sensitivity at baseline or mechanical sensi-
tivity in the contralateral paw in the SNI model and did
not affect spontaneous locomotor activity. A study using
a conditional Dicer knockout mice found that nociceptor
miRNA transcripts are required for lowering peripheral
pain thresholds in inflammatory hyperalgesia; nociceptor
specific deletion of Dicer, an enzyme required for gener-
ation of miRNAs, prevents the development of inflam-
matory hyperalgesia [31]. Based on these and our present
findings it is unlikely that the inhibition of persistent
hyperalgesia by miR-124 treatment in our study is
mediated by inhibition of neuronal hypersensitivity or by
impaired motor function.
Intraplantar IL-1β administration did not have any
effect on miR-124 expression in spinal cord microglia
from control WT mice, whereas it significantly reduced
miR-124 levels in microglia from LysM-GRK2+/− mice.
This finding indicates that low GRK2 in microglia/
macrophages sensitizes these cells for an intraplantar IL-
1β-induced decrease in miR-124 expression in spinal
cord microglia. The question arises how intraplantar
administration of IL-1β induces a decrease in microglial
miR-124 levels. Interestingly, in vitro it has been shown
that co-culture of bone marrow derived macrophages
with primary neurons reduces the level of macrophage
miR-124 [1]. These findings indicate that neuronal
signals can directly regulate the expression of miR-124
in macrophage- like cells. It is known that peripheral
nociceptors express IL-1β receptors and triggering of
these receptors results in direct sensitisation of the
nociceptor [32]. Therefore, it is conceivable that con-
comitantly, neuronal signals transmitted to the spinal
cord induce a reduction in miR-124 and thereby induce
a M1 type spinal cord microglia activation. Our finding
that only in mice with low GRK2 in microglia/macro-
phages miR-124 levels in spinal cord microglia are
reduced in response to intraplantar IL-1β may point to a
contribution of a GPCR-mediated signal to nociceptor-
to-microglia signaling. However, GRK2 is also known to
regulate cellular signaling at various levels downstream
of the membrane receptors. Thus, also increased signal-
ing independently of GPCRs in GRK2-deficient spinal
cord microglia/macrophages may contribute to the seen
decrease in miR-124 expression in microglia/macrophages
from LysM-GRK2+/− mice after intraplantar IL-1β.
Conclusions
We propose that low spinal microglia/macrophage GRK2
levels promote a transition to persistent hyperalgesia via
impaired microglial miR-124 regulation, and consequently
an impaired spinal M1/M2 balance. This model is sup-
ported by our findings that treatment with intrathecal ad-
ministration of miR-124 normalized the expression of M1
and M2 markers in LysM-GRK2+/− mice and inhibited
the development of IL-1β-induced persistent hyperalgesia
in these mice. The broader relevance of our results is sup-
ported by our finding that miR-124 treatment reversed
persistent hyperalgesia induced by a high dose of carra-
geenan and prevented development of hyperalgesia in the
SNI model of chronic neuropathic pain. In conclusion,
miR-124 might represent a novel option for the treatment
of chronic pain.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This study was supported by NIH grants RO1 NS 073939 and RO1 NS 074999
to AK.
Authors’ contributions
HLDM designed and performed experiments, and drafted the manuscript.
XJH and QLML performed experiments and revised the manuscript. JZ
performed immunohistochemistry and data analysis. CJH and AK designed
experiments, supervised data analysis, and revised the manuscript. All
authors have read and approved the final manuscript.
Received: 17 April 2012 Accepted: 25 June 2012
Published: 25 June 2012
References
1. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL:
MicroRNA-124 promotes microglia quiescence and suppresses EAE by
deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med
2011, 17:64–70.
Willemen et al. Journal of Neuroinflammation 2012, 9:143 Page 9 of 10
http://www.jneuroinflammation.com/content/9/1/143
2. Clark AK, Grist J, Al-Kashi A, Perretti M, Malcangio M: Spinal cathepsin S
and fractalkine contribute to chronic pain in collagen induced arthritis.
Arthritis Rheum 2011, 64:2038–47.
3. DeLeo JA, Yezierski RP: The role of neuroinflammation and neuroimmune
activation in persistent pain. Pain 2001, 90:1–6.
4. Milligan ED, Watkins LR: Pathological and protective roles of glia in
chronic pain. Nat Rev Neurosci 2009, 10:23–36.
5. Ren K, Dubner R: Interactions between the immune and nervous systems
in pain. Nat Med 2010, 16:1267–1276.
6. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier
SF: Norman Cousins Lecture. Glia as the “bad guys”: implications for
improving clinical pain control and the clinical utility of opioids. Brain
Behav Immun 2007, 21:131–146.
7. Zheng W, Ouyang H, Zheng X, Liu S, Mata M, Fink DJ, Hao S: Glial
TNFalpha in the spinal cord regulates neuropathic pain induced by HIV
gp120 application in rats. Mol Pain 2011, 7:40.
8. Eijkelkamp N, Heijnen CJ, Willemen HL, Deumens R, Joosten EA, Kleibeuker
W, Den HI, van Velthoven CT, Nijboer C, Nassar MA, et al: GRK2: a novel
cell-specific regulator of severity and duration of inflammatory pain.
J Neurosci 2010, 30:2138–2149.
9. Willemen HL, Eijkelkamp N, Wang H, Dantzer R, Dorn GW, Kelley KW,
Heijnen CJ, Kavelaars A: Microglial/macrophage GRK2 determines
duration of peripheral IL-1beta-induced hyperalgesia: contribution of
spinal cord CX3CR1, p38 and IL-1 signaling. Pain 2010, 150:550–560.
10. Eijkelkamp N, Wang H, Garza-Carbajal A, Willemen HL, Zwartkruis FJ, Wood
JN, Dantzer R, Kelley KW, Heijnen CJ, Kavelaars A: Low nociceptor GRK2
prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to
Epac/Rap1, protein kinase Cepsilon, and MEK/ERK. J Neurosci 2010,
30:12806–12815.
11. Jimenez-Sainz MC, Murga C, Kavelaars A, Jurado-Pueyo M, Krakstad BF,
Heijnen CJ, Mayor F Jr, Aragay AM: G protein-coupled receptor kinase 2
negatively regulates chemokine signaling at a level downstream from G
protein subunits. Mol Biol Cell 2006, 17:25–31.
12. Kleibeuker W, Jurado-Pueyo M, Murga C, Eijkelkamp N, Mayor F Jr, Heijnen
CJ, Kavelaars A: Physiological changes in GRK2 regulate CCL2-induced
signaling to ERK1/2 and Akt but not to MEK1/2 and calcium.
J Neurochem 2008, 104:979–992.
13. Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A,
Crespo P, Mayor F Jr, Murga C: Phosphorylation of p38 by GRK2 at the
docking groove unveils a novel mechanism for inactivating p38MAPK.
Curr Biol 2006, 16:2042–2047.
14. Vroon A, Heijnen CJ, Kavelaars A: GRKs and arrestins: regulators of
migration and inflammation. J Leukoc Biol 2006, 80:1214–1221.
15. Kavelaars A, Eijkelkamp N, Willemen HL, Wang H, Carbajal AG, Heijnen CJ:
Microglial GRK2: a novel regulator of transition from acute to chronic
pain. Brain Behav Immun 2011, 25:1055–1060.
16. Fenn AM, Henry CJ, Huang Y, Dugan A, Godbout JP: Lipopolysaccharide-
induced interleukin (IL)-4 receptor-alpha expression and corresponding
sensitivity to the M2 promoting effects of IL-4 are impaired in microglia
of aged mice. Brain Behav Immun 2011, 26:766–77.
17. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P:
Characterization of the microglial phenotype under specific pro-
inflammatory and anti-inflammatory conditions: effects of oligomeric
and fibrillar amyloid-beta. J Neuroimmunol 2009, 210:3–12.
18. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive
method for measuring thermal nociception in cutaneous hyperalgesia.
Pain 1988, 32:77–88.
19. Decosterd I, Woolf CJ: Spared nerve injury: an animal model of persistent
peripheral neuropathic pain. Pain 2000, 87:149–158.
20. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative
assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994,
53:55–63.
21. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER, Graf T: PU.1 and
C/EBPalpha/beta convert fibroblasts into macrophage-like cells. Proc Natl
Acad Sci U S A 2008, 105:6057–6062.
22. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM,
Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, et al:
Enhancement of hematopoietic stem cell repopulating capacity and
self-renewal in the absence of the transcription factor C/EBP alpha.
Immunity 2004, 21:853–863.
23. Bourlier V, Zakaroff-Girard A, Miranville A, De BS, Maumus M, Sengenes C,
Galitzky J, Lafontan M, Karpe F, Frayn KN, et al: Remodeling phenotype of
human subcutaneous adipose tissue macrophages. Circulation 2008,
117:806–815.
24. Fujiu K, Manabe I, Nagai R: Renal collecting duct epithelial cells regulate
inflammation in tubulointerstitial damage in mice. J Clin Invest 2011,
121:3425–3441.
25. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG:
Identification of two distinct macrophage subsets with divergent effects
causing either neurotoxicity or regeneration in the injured mouse spinal
cord. J Neurosci 2009, 29:13435–13444.
26. Komori T, Morikawa Y, Inada T, Hisaoka T, Senba E: Site-specific subtypes of
macrophages recruited after peripheral nerve injury. Neuroreport 2011,
22:911–917.
27. Haraguchi K, Kawamoto A, Isami K, Maeda S, Kusano A, Asakura K, Shirakawa
H, Mori Y, Nakagawa T, Kaneko S: TRPM2 contributes to inflammatory and
neuropathic pain through the aggravation of pronociceptive
inflammatory responses in mice. J Neurosci 2012, 32:3931–3941.
28. Honore P, Wade CL, Zhong C, Harris RR, Wu C, Ghayur T, Iwakura Y,
Decker MW, Faltynek C, Sullivan J, et al: Interleukin-1alphabeta
gene-deficient mice show reduced nociceptive sensitivity in models of
inflammatory and neuropathic pain but not post-operative pain. Behav
Brain Res 2006, 167:355–364.
29. Bai G, Ambalavanar R, Wei D, Dessem D: Downregulation of selective
microRNAs in trigeminal ganglion neurons following inflammatory
muscle pain. Mol Pain 2007, 3:15.
30. Brandenburger T, Castoldi M, Brendel M, Grievink H, Schlosser L,
Werdehausen R, Bauer I, Hermanns H: Expression of spinal cord
microRNAs in a rat model of chronic neuropathic pain. Neurosci Lett 2012,
506:281–286.
31. Zhao J, Lee MC, Momin A, Cendan CM, Shepherd ST, Baker MD, Asante C,
Bee L, Bethry A, Perkins JR, et al: Small RNAs control sodium channel
expression, nociceptor excitability, and pain thresholds. J Neurosci 2010,
30:10860–10871.
32. Eijkelkamp N, Heijnen CJ, Carbajal AG, Willemen HL, Wang H, Minett MS,
Wood JN, Schedlowski M, Dantzer R, Kelley KW, et al: GRK6 acts as a critical
regulator of cytokine-induced hyperalgesia by promoting PI3kinase- and
inhibiting p38-signaling. Mol Med 2012, 18:556–564. doi:10.2119/
molmed.2011.00398.
doi:10.1186/1742-2094-9-143
Cite this article as: Willemen et al.: MicroRNA-124 as a novel treatment
for persistent hyperalgesia. Journal of Neuroinflammation 2012 9:143.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Willemen et al. Journal of Neuroinflammation 2012, 9:143 Page 10 of 10
http://www.jneuroinflammation.com/content/9/1/143
